Terumo Dives Into China DES Market With Essen Springboard
Executive Summary
Terumo is adding China to its existing global drug-eluting stent (DES) sales network, with the agreed acquisition of Beijing-based Essen Technology. This is a modest acquisition for the Japanese group but could give it a springboard into a potentially lucrative and important DES market.
You may also be interested in...
Market Intel: The Changing Dynamics Of Newer-Generation Drug-Eluting Stents
The global vascular stents market is expected to reach $8.8bn by 2021, driven primarily by the growing prevalence of cardiovascular disease, the leading cause of death worldwide. Limitations of current stent products are fueling innovations by the three big heart players - Abbott, Boston Scientific and Medtronic - as well as startups to develop next-generation drug-eluting and bioresorbable stents that can reduce the risk of adverse event. This feature looks more closely at the competitive landscape of the overall vascular stent market focusing in particular on the changing dynamics of drug-eluting stents, which is the largest and second-fastest segment in this overall market, including its use for treating peripheral artery disease, along with physician surveys and perspectives.
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.